[18F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial.
Rachel M GlicksmanUr MetserJohn ValliantPeter W ChungNeil E FleshnerRobert G BristowDavid GreenAntonio FinelliRobert HamiltonTeodor StanescuDouglas HusseyCharles CattonMary GospodarowiczPadraig WardeAndrew BayleyStephen BreenDoug VinesDavid A JaffrayAlejandro BerlinPublished in: BMJ open (2020)
NCT03160794.
Keyphrases
- prostate cancer
- contrast enhanced
- pet ct
- computed tomography
- positron emission tomography
- magnetic resonance imaging
- radical prostatectomy
- image quality
- dual energy
- magnetic resonance
- diffusion weighted imaging
- rectal cancer
- open label
- prognostic factors
- pet imaging
- randomized controlled trial
- cell therapy
- smoking cessation